Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system
about
Synthetic biology and therapeutic strategies for the degenerating brain: Synthetic biology approaches can transform classical cell and gene therapies, to provide new cures for neurodegenerative diseasesArgonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liverGadolinium embedded iron oxide nanoclusters as T1-T2 dual-modal MRI-visible vectors for safe and efficient siRNA deliveryPreclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing.Polymerase II promoter strength determines efficacy of microRNA adapted shRNAsIn vivo gene knockdown in rat dorsal root ganglia mediated by self-complementary adeno-associated virus serotype 5 following intrathecal delivery.Transcriptomic analysis of genetically defined autism candidate genes reveals common mechanisms of actionCombined genetic attenuation of myelin and semaphorin-mediated growth inhibition is insufficient to promote serotonergic axon regeneration.Safe, long-term hepatic expression of anti-HCV shRNA in a nonhuman primate modelMolecular dissection of human Argonaute proteins by DNA shuffling.A microRNA embedded AAV α-synuclein gene silencing vector for dopaminergic neurons.RNA interference-based therapy for spinocerebellar ataxia type 7 retinal degeneration.Development of gene therapy for treatment of age-related macular degeneration.shRNA off-target effects in vivo: impaired endogenous siRNA expression and spermatogenic defects.Cell type specific, traceable gene silencing for functional gene analysis during vertebrate neural development.Opposing role for Egr3 in nucleus accumbens cell subtypes in cocaine action.Viral delivery of shRNA to amygdala neurons leads to neurotoxicity and deficits in Pavlovian fear conditioningOff Target, but Sequence-Specific, shRNA-Associated Trans-Activation of Promoter Reporters in Transient Transfection Assays.Aberrant Purkinje cell activity is the cause of dystonia in a shRNA-based mouse model of Rapid Onset Dystonia-Parkinsonism.Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates.Recent advances in RNA interference therapeutics for CNS diseases.Studies of efficacy and liver toxicity related to adeno-associated virus-mediated RNA interference.Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines.Recombinant AAV as a platform for translating the therapeutic potential of RNA interference.RUSH and CRUSH: a rapid and conditional RNA interference method in mice.Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators.Antisense-mediated RNA targeting: versatile and expedient genetic manipulation in the brain.Prospect of induced pluripotent stem cell genetic repair to cure genetic diseases.Lentiviral vector-mediated RNA silencing in the central nervous system.Gene therapy strategies for the treatment of spinal cord injury.The application of RNAi-based treatments for inflammatory bowel disease.Clinical translation of RNAi-based treatments for respiratory diseases.Lentiviral vectors encoding short hairpin RNAs efficiently transduce and knockdown LINGO-1 but induce an interferon response and cytotoxicity in central nervous system neurones.Intraperitoneal administration of AAV9-shRNA inhibits target gene expression in the dorsal root ganglia of neonatal mice.Dissecting microRNA dysregulation in age-related macular degeneration: new targets for eye gene therapy.The dose can make the poison: lessons learned from adverse in vivo toxicities caused by RNAi overexpression.Caspase-3 and GFAP as early markers for apoptosis and astrogliosis in shRNA-induced hippocampal cytotoxicity.AAV-mediated expression of BAG1 and ROCK2-shRNA promote neuronal survival and axonal sprouting in a rat model of rubrospinal tract injury.An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons.Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design.
P2860
Q26830610-6D9D3291-CE3E-4F6C-B866-E2793004072DQ30434933-E2EB30A2-DCFD-4271-8920-AEB6461B692EQ30657167-71AE0BD9-0429-4A65-8EB8-A06E546130BFQ33752590-87FB4091-1A8F-410D-8EC9-65ACDE5D37BAQ34059602-D9E2D988-7814-45CC-BDAD-7105368AD432Q34189539-4A731398-CD8C-4729-9A37-1A9C4AD4CA4BQ34249424-9FEAD7AC-6818-4279-890E-550F7411D371Q34282446-7727410D-55DD-40CA-91A7-F6D8CA61C321Q34284247-695FA48E-7BFF-405C-B42B-DB9CF34672B1Q34763313-8F23B3D3-53B8-41E2-8224-B5A772812A4AQ34795038-E68980F4-BBC8-4257-B568-ADAFD0769041Q35156007-223F0D0E-EB92-47FE-8804-E03444E9F640Q35192906-C4A6C352-722D-4C5E-8315-3539D10133BBQ35195510-059716EB-95C5-4A09-AE52-666F77EDF5CAQ35468232-34EF8D09-5C24-4309-84D3-874B4C12A44EQ35625766-31261FF1-69FB-47B0-94AB-C4359F6611D3Q36055122-B09971AE-1838-49CA-865E-987B9ACC719AQ36224846-68933402-2209-4CB5-B482-4157398B0F14Q36269315-28C8E678-3702-41BF-935E-4E746273672FQ36543516-7D9A8484-E86D-4A6F-BBCC-F445EFE1FCCBQ36983193-FBC3434B-D1D4-4E0C-9D0A-AE1743DCBE0EQ37105696-C2EAD57B-176F-49CD-B154-29287F4DD21FQ37327641-7639ACC0-C4DD-40BD-AC9E-E5BCEC37BFFAQ37696045-B228CD5B-8F41-4FC3-9C31-EA1E18E3FF18Q37700966-ED77F36C-9F04-4DDF-8581-495ADA657AC8Q37809086-8EC41BE2-DE07-4CD6-A995-31B0961CAF16Q37910743-C31523E2-4430-4E98-AE82-B94ED5FCF177Q37997007-4FB5B822-47FA-49DE-96D3-91FF5AD4022EQ38148784-02D99F40-DC6C-40E1-8490-F1443B28824FQ38226668-D8A83044-E835-4713-BA26-9A507925A6FAQ38382964-94CA47F1-9133-4375-B0D7-9205386250E0Q38383297-98312525-3FD6-416D-8AE4-BC58D8B9CBE3Q38463583-1BDD50F9-BFC5-4A83-B9A0-C9A73E3A3DCCQ39124150-2E6A97F7-6375-4A5F-AE53-FEC50A78E16EQ39167698-8CBAD456-0730-4F34-80AF-CB153ACADBC7Q39693289-A92612B5-0317-4CC6-8CAC-BD0B78D04E63Q40342529-2A5F9496-13D5-42F8-AF8E-83E1DE135992Q41162349-B49C9842-628F-4969-9C27-28544B638467Q41874717-41DE7D5B-F0CB-4BB1-97EF-FC37C945C6F5Q41983597-D6828DDB-B590-41B7-880B-DAEEEAF3BEF0
P2860
Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Cellular toxicity following ap ...... rference in the nervous system
@ast
Cellular toxicity following ap ...... rference in the nervous system
@en
Cellular toxicity following ap ...... ference in the nervous system.
@nl
type
label
Cellular toxicity following ap ...... rference in the nervous system
@ast
Cellular toxicity following ap ...... rference in the nervous system
@en
Cellular toxicity following ap ...... ference in the nervous system.
@nl
prefLabel
Cellular toxicity following ap ...... rference in the nervous system
@ast
Cellular toxicity following ap ...... rference in the nervous system
@en
Cellular toxicity following ap ...... ference in the nervous system.
@nl
P2860
P356
P1433
P1476
Cellular toxicity following ap ...... rference in the nervous system
@en
P2093
Erich M Ehlert
Joost Verhaagen
P2860
P2888
P356
10.1186/1471-2202-11-20
P577
2010-02-18T00:00:00Z
P5875
P6179
1013573919